A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

NCT03381066 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

225

Enrollment

OTHER

Sponsor class

Conditions

Completely Resected NSCLC With Common EGFR Mutations

Interventions

DRUG: gefitinib, pemetrexed,cisplatin
DRUG: Vinorelbine, cisplatin

Sponsor

Yonsei University